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1Executive summary
The use of mathematical modelling to inform and support tuberculosis (TB) 
policy-making has been encouraged by major funders and adopted by several 
high-burden countries. These quantitative planning exercises are undertaken to 
provide evidence for proposed interventions, improve the impact of TB funding 
and support funding applications. In recent years, a number of technical assistance 
providers have developed mathematical models and technical assistance capacity 
to support in-country TB policy decisions, and it is expected that the demand for 
technical assistance to support TB modelling will increase. 
The WHO Global Task Force on TB Impact Measurement provides global oversight 
to ensure that assessments of progress towards ending TB at global, regional and 
country levels are as rigorous, robust and consensus based as possible. The Task 
Force supports countries to improve the analysis and use of TB data for policy, 
planning and programmatic action, and is committed to the ongoing improvement 
of model-based policy analysis as a tool for strategic planning and budgeting.
This document aims to provide concrete, pragmatic guidance for how TB modelling 
and related technical assistance is undertaken to support country decision-making. 
The target audience for this document are the participants and stakeholders in 
country-level TB modelling efforts, including the individuals who build and apply 
models; policy-makers, technical experts and other members of the TB community; 
international funding and technical partners; and individuals and organizations 
engaged in supporting TB policy-making. 
The document describes 10 principles for country-level TB modelling: 
1. Relevance: Modelling should assess the policies and outcomes relevant to the 
country context and decision being made.
2. Realism: Modelling should explicitly consider implementation challenges 
that may reduce the effectiveness or increase the costs of interventions when 
introduced into routine practice, and should examine the plausibility of 
assumptions required for policy success.
EXECUTIVE SUMMARY
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3. Appropriateness of model structure: The model design should be justified in 
terms of the policy questions and local context being considered – the structure 
should be sufficiently detailed to represent the mechanisms generating policy 
outcomes but avoid unnecessary complexity.
4. Consideration of all evidence: Modelling should consider all available 
evidence relevant to the decision problem.
5. Validation: Where possible, model results should be compared with evidence 
not used for model parameterization or calibration, to under stand the 
consistency of modelling results with other evidence.
6. Informativeness: Modelled analyses should report a rich set of results 
describing policy consequences for a range of outputs and outcomes, to 
provide a deeper understanding of the scenarios being modelled and model 
functioning.
7. Transparency: Modelling results should be accompanied by a clear description 
of evidence that supports the main findings, the limitations of the modelling 
approach, uncertainty in modelled estimates and the sensitivity of results to 
different assumptions. Conflicts of interest should be avoided if possible, but 
where they are unavoidable they should be described explicitly.
8. Timeliness: Modelling activities should be organized to provide results at the 
time they are required for decision-making.
9. Country ownership: Modelling should be conducted with the full participation 
of local stakeholders at each stage of the process.
10. Iteration: Modelling should involve an iterative process of engagement, and 
should be reconsidered in light of new evidence.
These principles cover the design and estimation of the mathematical models 
themselves, as well as the approaches used to identify and synthe size evidence, 
and incorporate modelling into the process of policy identification and comparison. 
The principles are intended to apply to the estimation of both epidemiological and 
economic outcomes, and be relevant to any country-level TB modelling exercise 
undertaken to inform policy-making. Each principle is accompanied by several 
“good practices” for operationalizing these principles. The document also provides 
case studies that give concrete examples of how these principles have been 
applied in typical modelling applications, and a description of how these principles 
map onto the sequence of activities involved in a typical modelling application. As 
a separate, parallel work-package to this guidance, the TB Modelling and Analysis 
Consortium has developed a catalogue1 of organizations currently engaged in 
1 See http://tb-mac.org/tb-mac-resource/model-catalogue/ 
3providing country technical assistance for TB modelling; the catalogue provides 
detailed infor mation on the capabilities, approaches and past history of both the 
models and the modelling teams.
For modellers, this guidance suggests approaches that can improve the quality, 
relevance and timeliness of modelling work undertaken to support country-
level planning. For non-modellers, it describes issues to consider when engaging 
modelling technical assistance to support a planning process, contributing to a 
modelling exercise, or reviewing the results of modelled analyses. The principles 
and practices identified in this guidance document do not represent sufficient 
conditions for achieving valid modelling results, and should be applied in 
conjunction with existing guidance focused on other relevant aspects of policy 
evaluation, such as those for economic evaluation. However, it is hoped that the 
routine application of these principles will improve the reliability, transparency and 
usefulness of modelling results for TB policy-making. 
Most of the principles and practices described in this guidance serve three higher-
level goals: that model-based policy evaluation makes the best use of available 
evidence; that modelling is incorporated into policy-making in a way that clearly 
recognizes the strengths and weaknesses of the modelled estimates; and that the 
modelling supports (rather than replaces) policy-making as a deliberative, country-
led process. While this guidance will not respond to all questions that arise in the 
context of a modelling exercise, it is intended to provide guidance on some of the 
major questions common to most country-level TB modelling applications.
EXECUTIVE SUMMARY
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CHAPTER 1
Introduction
1.1 Policy context 
In the era of the Sustainable Development Goals (SDGs) and the End TB Strategy, 
the global tuberculosis (TB) community has set ambitious targets for reductions in 
TB incidence and mortality, including the reduction of global TB incidence by 80% 
by 2030 and by 90% by 2035, and of global TB mortality by 90% by 2030 and by 
95 by 2035, compared with their 2015 levels (1, 2). To achieve these targets, national 
TB programmes (NTPs) need to identify ways to accelerate their efforts in TB 
diagnosis, care and prevention. This could include adopting new technology and 
interventions, expanding the coverage and quality of existing services, intervening 
on the broader social and economic determinants of TB infection and disease, 
and implementing actions to ameliorate the economic burden of TB and TB care. 
Countries are developing plans to accelerate TB care and prevention, and have 
received global guidance to enable these efforts, including the Global Plan to End 
TB (3) and the Essentials to End TB (4), which set out guidance and approaches for 
operationalizing the End TB Strategy. 
Since 2006, the WHO Global Task Force on TB Impact Measurement has provided 
global oversight to ensure that assessments of progress towards global TB targets 
and milestones are, as far as possible, rigorous, robust and consensus based (5-
7). Until 2015, the focus was on targets set within the context of the Millennium 
Development Goals (MDGs) and the Stop TB Strategy (2006–2015). Since 2016, the 
focus has been on the targets and milestones of the SDGs and the End TB Strategy. 
In 2016, the Task Force also agreed on a new strategic area of work called “Analysis 
and use of TB data”, which aims to support countries to improve their analysis and 
use of TB data for policy, planning and programmatic action. This strategic area of 
work includes analyses of TB-related inequalities; projections of disease burden 
and intervention impact; and provision of guidance, tools and capacity-building. As 
part of this new area, the Task Force is committed to the ongoing improvement of 
model-based policy analysis as a tool for strategic planning and budgeting.
51.2 Rationale for modelling
Mathematical models describe a mechanistic relationship between the actions 
undertaken by TB programmes to combat TB and the consequences of these 
actions. The consequences can include changes in summary health outcomes 
such as disability-adjusted life years (DALYs) averted or life years saved, measures 
of service use, trends in TB incidence and mortality, economic burden and budget 
impact. Mathematical modelling can incorporate a wide range of evidence such 
as clinical evidence on disease natural history, routine reporting data describing 
health programme performance, and economic data on costs and budget limits. 
It can then synthesize these inputs to estimate outcomes that would be expensive 
or impractical to assess empirically. This is particularly true for TB policy, where 
the benefits of an intervention typically extend beyond the set of individuals who 
receive the intervention, and are realized over a long period. When based on strong 
empirical evidence, modelling can be thought of as an approach for principled 
extrapolation, providing an understanding of how policy choices will affect 
future health and economic outcomes. Clearly, mathematical modelling can be a 
useful tool for informing national and subnational TB policy-making, programme 
planning and resource mobilization. 
Sometimes a choice will need to be made between modelling and empirical studies, 
but generally these two forms of enquiry should be seen as complementary – 
without good empirical data, modelling is unlikely to provide accurate predictions, 
and without modelling it can be hard to know the exact implications of empirical 
findings.
1.3 Demand for modelling
It is becoming increasingly common for countries to use modelling to evaluate 
TB policy options, because of the increasing attention of local and international 
stakeholders on what it will take to achieve the End TB Strategy targets, and the 
need to make efficient choices (within the resource limits available) among the 
increasing range of TB policy options. New diagnostic and treatment technologies 
are becoming available (8–10), and modelling can be used to understand how these 
technologies can best be incorporated into programmatic efforts.
A survey by the TB Modelling and Analysis Consortium1 (TB MAC) of groups 
providing technical assistance for TB modelling indicated that, by January 2018, 
more than 20 low- and middle-income countries across the WHO regions of Africa, 
the Eastern Mediterranean, Europe, South-East Asia and the Western Pacific had 
used modelling to inform applications to the Global Fund to Fight AIDS, Tuberculosis 
and Malaria (Global Fund), and in the development of national strategic plans and 
1 See www.tb-mac.org
CHAPTER 1: INTRODUCTION
6 GUIDANCE FOR COUNTRY-LEVEL TB MODELLING
other domestic funding applications. A notable example comes from South Africa, 
where modelling evidence supported the financing and allocation of a TB budget 
of R 500 million (US$ 40 million) (11). As experience progresses, modelling is likely to 
become a more routine part of TB monitoring and evaluation workflows, which in 
turn will feed into funding applications. 
1.4 Current challenges
As experience with country-level TB modelling has grown, several challenges have 
become evident:
 limitations in the data and evidence available to inform modelled analyses;
 limitations in the ability of models to represent complex policy scenarios, such 
as targeting of risk groups not represented in existing models;
 difficulty in anticipating factors that could negatively affect the out comes of 
modelled policy scenarios, particularly those that involve novel interventions or 
aggressive expansion of existing services;
 differences in the modelling and estimation approaches taken by modelling 
teams, with the potential that different models could produce different policy 
advice, despite having the same country context and policy question;
 scarcity of human resources (globally and within high-burden countries) to 
meet the demand for modelling technical assistance, and lack of information 
for country TB programmes on what modelling support is available; and 
 differences in the level of experience, understanding and expectations of the 
modelling process by in-country stakeholders and international funders; and, 
related to this, differences in the confidence placed in modelled analyses by 
local and international stakeholders. 
Studies that have compared multiple models have found substantial variation 
between modelling results, even when they are investigating standardized policy 
scenarios (12–15). Modelling is often used to forecast the impact of policies that are 
more aggressive or implemented at higher coverage than previously observed in 
routine programmes, and this need to extrapolate beyond current programmatic 
experience introduces much greater uncertainty into modelling results. Variation in 
modelling outcomes has consequences for decision-making, with the ordering of 
policy options by cost–effectiveness criteria differing among models (12, 15). Further 
limitations in the robustness of model predictions may be observed in countries 
with weak TB surveillance data, where new data from cross-sectional TB prevalence 
surveys can result in significant changes to estimates of disease burden. These 
revisions to the understanding of recent and current epidemiology can alter future 
disease projections and potentially influence policy choices.
7Box 1.1 summarizes the points to consider when deciding whether using a model is 
appropriate in a particular situation.
1.5 Existing guidance
Despite the increasing role of TB modelling, there are currently no formal guidance 
documents for NTPs, modellers and international partners on how to use TB models 
to support country-level decision-making. Several guidance documents exist in 
related fields, often separated into guidance on specific methodological domains; 
for example, epidemiological modelling, costing and economic modelling, 
and algorithms for identifying optimal budget allocations. The most notable 
contributions include recommendations by the task force of the International 
Society for Pharmacoeconomics and Outcomes Research (ISPOR) (16–22) and 
recently developed reference evaluation (23, 24) and costing (25). Relevant disease-
specific guidance includes contributions from the fields of HIV (26, 27) and human 
papillomavirus (HPV) (28, 29), and recent TB-specific guidance focused on the use 
of latent infection treatment for immigrants in low-burden settings (30). These 
documents were used to inform the guidance outlined here.
1.6 This guidance
This guidance document is designed to address the needs outlined above; that is, 
an increased demand for model-based policy evaluation, concern about observed 
heterogeneity in results, and a desire to see more transparent links between 
modelled evidence and the empirical data that support them. It describes how 
mathematical modelling can be used to help country TB stakeholders make 
decisions, and it includes guidance on modelling approaches, use of data, reporting 
of results and expectations for various actors throughout the process.
The guidance is organized as a set of 10 principles (Chapter 3). Each principle 
is accompanied by several “good practices”, which suggest concrete steps that 
could be taken to operationalize the principles. This is followed by a discussion of 
the roles and responsibilities of various actors in the modelling process, as well as 
how the principles align with particular activities in a typical modelling application 
(Chapter 4).
As a separate but complementary work-package to this guidance document, 
aimed at a similar audience, TB MAC has worked with modelling groups currently 
engaged in providing technical assistance to countries to develop a catalogue1 that 
provides detailed information on the capabilities, approaches and history of both 
the models and the modelling teams.
1 See https://docs.google.com/spreadsheets/d/1vEDYkXJbMhftWDojnWOuVDbH6h9__Jezg0xsqH5MfJo/
edit#gid=287565855 
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BOX 1.1  When to use a model
Modelling can provide a logical framework for projecting TB burden and budget 
requirements, and assessing the consequences of different policy options. In that 
role, models can add substantial value to NTP planning and prioritization, advocacy 
efforts and decisions on donor funding. However, a formal modelling exercise will 
not be required to answer all questions around TB policy and programme strategy. 
Instead, modelling should be considered alongside other approaches used to 
answer policy questions, including direct extrapolation from empirical studies 
conducted in the setting, generalizing from similar programmes or countries, and 
expert opinion. 
If the goal is to predict future health outcomes or resource needs, any approach 
that is used will involve important assumptions. Although simpler approaches 
may appear to require fewer assumptions, this may be because assumptions are 
not explicit. For example, predicting the outcomes of a programme by directly 
extrapolating research study results can make strong assumptions that health 
burden, care-seeking behaviour and the capabilities of health service providers are 
similar between the research study and routine health services. In this circumstance, 
a formal model may allow future health outcomes to be predicted with more 
realistic assumptions. However, to answer many programmatic questions it may 
not be desirable to predict long-term health outcomes. For example, to identify 
the best approach to improve treatment completion it may not be necessary to 
estimate the impact on distal outcomes such as cure rates and survival; rather, 
it may be sufficient to assume that improvements in treatment completion will 
improve these other outcomes proportionally.
Compared to other approaches, a formal modelling study will typically require 
more time and effort to undertake; also, it may require sustained engagement from 
local stakeholders if it is to generate useful policy advice. Given the costs and effort 
required for modelling, this approach is most likely to be useful where: 
 decision-makers are considering an important policy decision (i.e. one that has 
substantial consequences for programme budgets or health outcomes, or that 
would restrict future policy options);
 policy options need to be considered in terms of their impact on long-term 
health and economic outcomes, rather than more proximal outcomes that could 
be estimated using simpler methods;
 there is adequate funding, time and technical capacity to implement the 
modelling application; and
 there is strong engagement by relevant decision-makers, including willingness 
to commit the time to scrutinize modelling assumptions and scenarios, and to 
act based on modelling results.
9CHAPTER 2
Development process, scope  
and target audience
2.1 Process and stakeholders
Motivated by the growing role of mathematical modelling in TB policy-making, 
and the apparent heterogeneity in modelling approaches and results, TB MAC was 
asked to develop guidance for country-level TB modelling. TB MAC is a modelling 
consortium funded by the Bill & Melinda Gates Foundation to provide coordination 
and technical assistance for TB modelling, under the oversight of the WHO 
Global Task Force on TB Impact Measurement. This guidance document has been 
developed by TB MAC in collaboration with key global stakeholders including WHO, 
the Global Fund, the Bill & Melinda Gates Foundation, the Stop TB Partnership, the 
World Bank and the United States Agency for International Development (USAID).
An initial outline of the document was prepared by a small writing committee 
(Nicolas A Menzies, C Finn McQuaid, Gabriela B Gomez and Rein MGJ Houben) 
and reviewed by a group of 30 expert stakeholders, including TB modellers, 
country users of TB models, and donors and advocates. Suggestions from these 
stakeholders were incorporated and a full draft of the guidance was developed. 
The draft was reviewed by the TB MAC committee and members of the WHO 
Global TB Programme for further comment. Following additional revisions, the 
draft guidance was presented and discussed at the TB MAC/WHO Task Force 2017 
annual meeting in Glion, Switzerland (18–22 September 2017), where comment was 
invited from a wider stakeholder group, including modelling groups, international 
stakeholders and funders, and other technical experts. Further review and input 
was provided after this meeting by country stakeholders and technical experts, 
and the final draft of this guidance was reviewed and endorsed by the WHO Global 
Task Force on TB Impact Measurement in May 2018. 
Individuals providing review and input into this guidance are listed in the 
Acknowledgements section.
2.2 Scope
The guidance focuses on the use of mathematical models to support national 
TB policy and planning, including applications to funding agencies such as the 
CHAPTER 2: DEVELOPMENT PROCESS, SCOPE AND TARGET AUDIENCE
10 GUIDANCE FOR COUNTRY-LEVEL TB MODELLING
Global Fund, USAID and the World Bank. It covers both the epidemiological and 
economic aspects of modelling, to capture the considerations that typically arise as 
part of projecting future epidemiological outcomes, evaluating the consequences 
of competing policy options, cost estimation, and analyses of cost–effectiveness 
and allocative efficiency. The scope of the guidance also includes issues related to 
how models are used to support country decision-making. Extending the scope of 
the guidance beyond the technical features of the models is deliberate, because 
the utility of modelling for country-level decision-making is greatly influenced 
by how the modelling tools are applied and integrated into the process of policy 
identification and comparison. 
The scope described above does not encompass all issues that will arise in the 
conduct of TB modelling more generally (e.g. modelling not explicitly linked to 
national planning and budgeting). However, many of the approaches promoted 
in this guidance document will be generalizable to other areas of TB modelling. 
More detailed guidance on particular aspects of policy evaluation is available in 
other documents, such as iDSI’s reference case for economic evaluation (24). This 
TB modelling guidance should be read in conjunction with other relevant guidance 
documents, as well as any additional criteria prescribed by funders or other 
stakeholders in the modelling process.
2.3 Target audience
The target audience for this document is the individuals who build or apply 
models for country-level TB decision-making. The content of this guidance is also 
relevant for other participants and stakeholders in country-level TB modelling 
efforts, including policy-makers, technical experts and other members of the TB 
community in affected countries; international funding and technical partners; 
and individuals and organizations engaged in supporting TB policy-making. 
For modellers, this guidance suggests approaches that can improve the quality, 
relevance and timeliness of modelling work undertaken to support country-
level planning. For non-modellers, it describes issues to consider when engaging 
modelling technical assistance to support a planning process or evaluate policy 
options, contributing to a modelling exercise or reviewing the results of modelled 
analyses.
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CHAPTER 3
Principles and good practices for  
country-level TB modelling
This chapter describes principles and good practices for country-level TB modelling. 
The principles do not represent sufficient conditions for achieving valid modelling 
results; however, if adopted they could improve the reliability, transparency and 
usefulness of modelling results for TB policy-making. A summary of the principles 
and good practices is provided in Table 3.1.
Most of the principles and practices summarized in Table 3.1 and explained in more 
detail in the rest of the chapter serve three higher-level goals: 
 that model-based policy evaluation makes the best use of available evidence;
 that modelling is incorporated into policy-making in a way that clearly expresses 
the strengths and weaknesses of the modelled estimates; and 
 that the modelling supports (rather than replaces) policy-making as a 
deliberative, country-led process. 
Although the principles and practices described in this document will not 
provide an answer to all of the questions that arise in the context of a modelling 
exercise, they do address the major questions common to most country-level TB 
modelling applications. Several short case studies are also provided as real-world 
examples of how the principles apply to modelling applications, and the roles and 
responsibilities of various stakeholders are discussed in Box 3.1.
CHAPTER 3: PRINCIPLES AND GOOD PRACTICES FOR COUNTRY-LEVEL TB MODELLING
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TABLE 3.1  Summary of principles and good practices for country-level  
TB modellinga
PRINCIPLE GOOD PRACTICE ACTOR
1. Relevance: 
Modelling should 
assess relevant policies 
and outcomes
1.1 Decision-makers, policy questions, 
constraints, outcomes and perspective 
should be determined before modelling 
begins
G ( ®
1.2 A clear description of policy scenarios 
should define all actions to be modelled G ( ®
2. Realism: Modelling 
should consider 
implementation 
challenges and 
examine requirements 
for policy success
2.1 Realistic assumptions should be made 
about policy costs and effectiveness ( ®
2.2 Analyses should consider the additional 
costs of service expansion as well as any 
effect on existing services
( ®
2.3 Where there is little prior experience of 
policies, sensitivity analyses should be 
conducted, and results appropriately 
labelled as speculative
®
2.4 The modelling process should remain 
objective ( ® U
2.5 Assumptions and evidence for the pace 
and success of implementation should 
be documented
( ®
2.6  Capacity limitations should be 
appropriately included in the analysis G ( ®
3. Appropriateness 
of model structure: 
Model design should 
be justified in terms of 
the policy questions 
being considered and 
avoid unnecessary 
complexity
3.1 The model used should represent major 
mechanisms generating TB outcomes in 
the given setting
®
3.2 Major structural decisions in the model 
should be justified ®
3.3 Model choice should be based on 
the appropriateness to the setting, 
evidence, policies and outcomes in 
question
®
4. Consideration 
of all evidence: 
Modelling should 
consider all available 
evidence relevant to 
the decision problem
4.1 A review of all pertinent evidence should 
be carried out ( ®
4.2 Evidence should be checked for quality 
and appropriateness ( ®
4.3 Conflicting evidence should be 
investigated ( ®
4.4  Routine data should be checked for 
appropriate use ( ®
4.5  Decisions informed by expert opinion 
should be validated where possible ( ®
4.6  The implications of parameter 
uncertainty on results should be 
investigated
( ®
4.7  Model calibration should be reported in 
full ( ®
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5. Validation: Results 
should be compared 
to evidence not 
used for model 
parameterization or 
calibration
5.1  Models should avoid broad claims of 
validity and actively test performance ®
5.2  Model results should be checked against 
local epidemiology and health service 
characteristics, as well as general TB 
epidemiology
( ®
5.3  Model sensitivity to assumptions should 
be checked ®
5.4  Results should be compared to 
other modelling results or empirical 
assessments where possible, or through 
consultation with stakeholders
G ( ®
5.5  Rates of decline in burden should be 
compared with historical evidence of 
limits in rates of decline
®
6. Informativeness: 
Modelling should 
report results for 
a wide range of 
outcomes
6.1  Analyses should report summary 
measures of health benefit (e.g. DALYs 
averted, QALYs saved)
®
6.2 Models should additionally report 
policy consequences for a wide range 
of epidemiological and programmatic 
outcomes
G ( ®
6.3 Analyses should disaggregate total cost 
estimates into categories relevant for 
budgeting (e.g. by payer, cost category 
and year)
( ®
6.4 Analyses should investigate the impact 
of different time horizons ®
7. Transparency: 
Reporting should 
include a description 
of supporting 
evidence, limitations, 
sensitivity analyses 
and conflicts of 
interest
7.1 Details of model structure and 
implementation should be made 
available in technical documentation
®
7.2 Policy and baseline scenarios should be 
fully described ( ®
7.3 A non-technical description of 
uncertainties, limitations, evidence 
sources and validation should 
accompany results
®
7.4 In contentious contexts, additional 
efforts should be made to seek 
engagement and agreement on the 
modelling approach from all important 
stakeholders 
G ( ® U
7.5 Conflicts of interest should be identified, 
managed and explicitly stated ( ®
7.6 An external review of the modelling 
analysis should be conducted where 
possible
®
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PRINCIPLE GOOD PRACTICE ACTOR
8. Timeliness: 
Modelling should 
provide results in time 
for decisions to be 
made
8.1  Planning should be conducted to ensure 
that results can be provided when they 
are required, including review/revision 
of scenarios and assumptions
G ( ® U
8.2  If the modelling process is curtailed in 
order to meet a deadline, drawbacks of 
this should be described
®
9. Country 
ownership: Modelling 
should be conducted 
through participation 
with local stakeholders 
9.1  Full engagement with local stakeholders 
should be gained G ( ® U
9.2  Plans to increase country capacity 
should be implemented where possible G ( ® U
9.3  Country input at each stage of the 
modelling process should be enabled G (
9.4  Modelling should be planned in the light 
of existing efforts in research, evaluation 
and surveillance
( ® U
9.5  Choice of modelling technical assistance 
provider should be determined by 
ability to meet decision-maker needs
G ( U
10. Iteration: 
Modelling should be 
an iterative process, 
and reconsidered 
given new evidence
10.1 Stakeholders should evaluate initial 
versions of the modelling approach, 
policy scenarios and results, and these 
should be revised if needed
G ( ® U
10.2 The sensitivity of the model to new 
evidence should be described ( ®
10.3 The validity of model projections should 
be reconsidered if early programmatic 
data show assumptions to be incorrect
( ®
DALY, disability-adjusted life year; QALY, quality-adjusted life year; TB, tuberculosis
a The “Actor” column suggests the lead actor(s) for each practice; that is, the individual or 
group primarily responsible for implementing the practice. Actors include 
 G in-country decision-makers
 ( in-country experts 
 ® modellers and 
 U international funders. 
 Other actors may also have a role in contributing towards practices or activities, or in creating 
the demand for them.
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BOX 3.1  Roles and responsibilities
When used to support country decision-making, modelling commonly involves the 
participation of multiple stakeholders:
 modellers, who are deeply familiar with how the model works, but potentially 
less familiar with local evidence, available options and preferences;
 other experts, who bring expertise in a relevant content area (e.g. local 
epidemiology, programme characteristics, or costing and budgeting);
 local decision-makers, who may have less time to be involved in the process of 
implementing the model but have a central role in setting the parameters of the 
planning exercise and are deeply interested in the results; and
 in some cases, external funders, who can be influential in defining the role of 
modelling through the criteria used to evaluate funding requests.
The task of implementing many of the principles described in this document lies 
mainly with the modellers, but there are responsibilities for all parties. It is hoped 
that this guidance will help all those involved in TB modelling to make these 
exercises more valid and useful for country decision-making.
To more easily identify responsibilities for different stakeholders, Table 3.1 includes 
a column of stakeholders, or actors, who would typically take responsibility in 
leading specific areas in the implementation of each good practice. Other actors 
may also have a contributory role, or a role through the creation of demand.
3.1 Principle 1 – Relevance
Modelling should assess the policies and outcomes relevant to the country 
context and decision being made. Without good engagement between those 
involved in planning and resource allocation, policy-makers, partners and analysts, 
it is all too easy for modelling to evaluate strategies that differ in important ways 
from those that are being considered by decision-makers. Where a pre-existing 
model is used for a new planning exercise, the model may be insufficiently tailored 
to the local context, or strategies may be excluded from consideration because 
they are not already built into the model. Ideally, the modelling exercise can be 
useful in shaping the policy scenarios being considered and identifying outcomes 
of interest. For example, the specificity required to parameterize a model can force 
CHAPTER 3: PRINCIPLES AND GOOD PRACTICES FOR COUNTRY-LEVEL TB MODELLING
In practice: Relevance (Principle 1) 
n During the application of a model to multiple countries, it became clear that 
there were important differences in the extent to which the quality of care in the 
private sector was an issue. To make the model relevant to different settings, the 
modelling team consulted with each of the country programmes, to ensure that 
assumed parameters were applicable to each setting.
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participants to think through the details of how a policy or new intervention would 
be implemented, the mechanisms through which it would affect costs and health 
outcomes, and how these should be summarized to inform the decision. 
3.1.1 Good practices (Principle 1 – Relevance)
GP1.1. The initial task in a modelling exercise is to define the decision problem and 
the question or questions that need to be answered. This involves scoping the 
following:
 Who is making the decision? This could be the NTP, ministry of health or a 
subnational government entity.
 What is the question or questions to which the decision-maker would like an 
answer?
 What are the constraints on the policies or interventions that can be chosen (e.g. 
a fixed budget cap, or only allocating funding within part of the TB portfolio)?
 What are the candidate policies or intervention scenarios to be considered? 
These could be defined using sources such as stakeholder opinion, national 
strategic documents or WHO policy guidance.
 What criteria and outcomes are to be used to compare policies or interventions?
 Is modelling the most appropriate approach to address the question or 
questions being asked?
 What costs are to be considered (i.e. what is the study perspective), and what is 
the relevant budget period?
Each of these questions should be answered before considering how modelling 
will be undertaken.
GP1.2. Policy or intervention scenarios to be evaluated using modelling should 
include a complete description of all actions required to implement the policy 
or interventions, sufficient to allow reasonable judgments to be made about the 
plausibility of the assumptions and the resource require ments for implementation.
3.2 Principle 2 – Realism 
Modelling should explicitly con sider implementation challenges that 
may reduce the effectiveness or increase the costs of inter ventions when 
intro duced into routine practice, and should examine the plausibility of 
assumptions required for policy success. Modelling is often called upon to 
evaluate novel interventions, or proposals to expand the coverage or quality of 
routine services above current levels. For these scenarios, there is generally less 
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information about their effects and costs (compared with established interventions) 
in typical programmatic settings. This can lead to overly optimistic projections 
of the effectiveness or cost–effectiveness of proposed policies or intervention 
scenarios, particularly when initial evidence is obtained in high-capacity clinical 
settings or for subpopulations where effect sizes are likely to be larger, or when 
there is external pressure for the modelling to “be ambitious”. Historical experience 
is likely to be the best starting point for modelling assumptions about the pace and 
success of implementation.
3.2.1 Good practices (Principle 2 – Realism)
GP2.1. Policy or intervention scenarios should make realistic assumptions about the 
likely effectiveness and costs of policies or interventions in the settings in which 
they will be introduced, as well as the pace and process of implementation. This will 
probably include imperfect compliance with details of the policy or interventions 
(e.g. as presented in clinical guidelines) by providers, and low uptake or adherence 
by the intended beneficiaries.
GP2.2. The resources required to expand service provision can be substantially 
different from the current average cost of routine services. Where scenarios involve 
increases in intervention coverage, cost analyses should account for any additional 
activities or investments required to expand services, as well as any potential 
economies (or diseconomies) of scale associated with changes in service volume. 
GP2.3. For policies or interventions with which there is little experience of what to 
expect in routine programmes, it is important to conduct sensitivity analyses and 
investigate situations that would lead to substantial attrition of impact, harmful 
externalities or increased costs. Similarly, it is useful to investigate scenarios 
that allow for incomplete or delayed adoption. If the empirical implementation 
evidence is weak or absent, results should be clearly labelled as speculative. 
GP2.4. One use of modelling is to generate evidence to advocate for specific 
policies, interventions or increased funding levels. However, if analytic choices 
are made with the intention of promoting a particular outcome, this can lead to 
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In practice: Realism (Principle 2)
During a country visit, discussions between the modelling team and staff 
from the NTP highlighted that screening protocols did not reflect the reality of 
implementation, with substantial variation found. Through triangulation with 
data from other national modelling efforts, and agreement with local experts, 
model assumptions were made that reflected actual practice, including barriers 
to implementation and associated time implications.
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misallocation of funding and a loss of credibility for modelling as a policy input. 
Therefore, preferences for a particular policy, intervention scenario or modelling 
outcome should not be allowed to influence analytic choices, such as assumptions 
about intervention effect sizes or uptake. If a modelled scenario does involve 
optimistic or contestable assumptions, these should be highlighted in the results.
GP2.5. Given the importance of implementation to success, the assumptions made 
about the pace and success of implementation should be documented, as well as 
the evidence basis for these assumptions.
GP2.6. Where capacity limitations are known to exist, it is preferable for these to be 
represented in the analysis. This can be achieved either by modelling the negative 
impact on other services that would result from expanding one programmatic area, 
or by including constraints in the analysis such that use of a particular resource 
cannot go above a known level. Ideally, analyses would also consider the costs and 
benefits of efforts to relax capacity constraints.
3.3 Principle 3 – Appropriateness of model structure 
The model design should be justified in terms of the policy questions and 
local context being considered – the structure should be sufficiently detailed 
to represent the mechanisms generating outcomes but avoid unnecessary 
complexity. Model development commonly involves numerous decisions about 
model structure, dealing with how to represent the population affected by a 
particular policy or intervention, and how to describe their transition through 
demographic and epidemiological processes, and access to or receipt of health 
care. These choices balance the following conflicting priorities:
 faithfully representing the process being modelled, which commonly leads 
to more detailed modelling approaches, such as greater heterogeneity of the 
modelled population, or more complicated functions describing health state 
transitions or the relationship between implemented activities and outcomes; 
and 
In practice: Appropriateness of model structure (Principle 3)
During application of a model in countries in Asia and Africa, it became clear that 
the model needed an appropriate structure to capture the complete screening 
population, including those who did not have TB and were at risk of being 
misdiagnosed (i.e. false positives) with TB. With this appropriate structure, the 
model was able to provide a more complete impression of resources needed (e.g. 
people screened) and potential negative consequences of proposed screening 
programmes.
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 developing a model whose processes are transparent, understandable and 
interpretable to both the modeller and the modelling audience, which is often 
better served by simpler, more parsimonious modelling approaches. 
Some structural choices will promote both of these aims simultaneously, but most 
will involve a trade-off between realism and parsimony. Moreover, the decision to 
add more detail on a particular part of the model will not necessarily improve the 
validity of the results, because as the overall complexity of a model increases, it can 
become more difficult to explain unexpected model results and identify errors. 
Similarly, given the constrained resources and short time frame commonly available 
for modelling applications, if the model runs slowly and requires substantial 
computing resources, this can limit the opportunities to fully investigate parameter 
uncertainty, assess all relevant policy scenarios and iteratively improve the analysis 
through feedback from modelling stakeholders.
3.3.1 Good practices (Principle 3 – Appropriateness of model structure)
GP3.1. Models should be able to represent the major mechanisms generating TB 
outcomes in a particular setting. For example, in settings with high levels of TB–
HIV coinfection, models should be able to represent the influence of HIV-associated 
immune suppression on TB natural history, as well as the impact of current and 
planned future levels of antiretroviral therapy coverage. Similarly, for settings 
with high proportions of drug-resistant TB, models should consider the influence 
of drug resistance on health outcomes and costs. These mechanisms can also 
describe programme functioning. For example, in analyses designed to examine 
improvements in case detection, it will generally be appropriate to model the 
full TB care cascade, rather than assume a single rate of treatment initiation for 
individuals with undiagnosed active TB.
GP3.2. Major structural decisions in the model should be justified in comparison 
to alternative approaches, and any limitations of the chosen structure clearly 
described. Where possible, alternatives to the model structure should be tested, 
to understand their implications for model results. Formal comparisons of different 
models or modelling approaches can be undertaken for important policy questions 
where structural uncertainty is a concern, although these comparisons are unlikely 
to be feasible in the context of a typical application.
GP3.3. If multiple models are available for use in a given analysis, the choice of 
model should be based on its relative ability to:
 represent key features of TB epidemiology, health service interactions and 
resource use in the setting of interest; 
 reflect the available evidence to inform model structure;
CHAPTER 3: PRINCIPLES AND GOOD PRACTICES FOR COUNTRY-LEVEL TB MODELLING
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 represent risk groups being considered by the policies or interventions of 
interest; 
 represent the mechanisms by which the policies or interventions of interest will 
have an effect; and 
 produce the outcomes of interest to decision-makers (including both costs and 
health outcomes). 
3.4 Principle 4 – Consideration of all evidence
Modelling should consider all available evidence relevant to the decision 
problem. Mathematical models specify a sequence of relationships that link the 
actions described under a policy or planning scenario to the health and economic 
outcomes of interest. Typically, many different sources of evidence are required 
to parameterize these relationships, and errors in any of these parameters will 
affect results. Although there will be finite resources (including time) available to 
collate inputs, all key data and evidence should be identified and incorporated to 
produce valid and accurate results. Where there is substantial uncertainty in key 
parameter inputs, it should be thoroughly investigated, and the implications of this 
uncertainty for conclusions drawn from the analysis should be reported alongside 
the main analytic results. Adjusting parameter values so that model predictions 
are consistent with observed data (model calibration) can improve the validity of 
future projections and increase confidence among the consumers of modelling 
results. However, calibration must be undertaken carefully to avoid overfitting and 
acknowledge potential biases in calibration data.
3.4.1 Good practices (Principle 4 – Consideration of all evidence)
GP4.1. Preparation of a model to answer a particular question should be 
accompanied by a thorough review of the evidence pertinent to the policy or 
planning scenario being evaluated. Although a new systematic review and meta-
In practice: Consideration of all evidence (Principle 4)
During a review of evidence to inform modelling related to the introduction of 
preventive therapy for contacts and active case finding (ACF), the modelling 
group identified important differences in the type of evidence available for these 
two interventions. Specifically, epidemiological evidence about the efficacy 
of ACF was available from cluster randomized trials, whereas evidence about 
the efficacy of preventive therapy was available from clinical studies at the 
level of individuals. The modelling report clarified the differences in the type of 
evidence available, and the limited evidence regarding the effectiveness of both 
interventions under programmatic conditions.
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analysis is unlikely to be feasible for all model parameters, it can be considered for 
influential model inputs, where existing reviews are insufficient. 
GP4.2. All evidence that might be used for modelling should be reviewed in terms 
of its quality (e.g. strength of study design and precision of measurement) and 
appropriateness for the given application. Often, there is a need for trade-offs 
between the strength of study design and the local relevance of data. Where the 
use of evidence requires generalization from a different setting or an intervention 
that is related but different, the assumptions required to do so should be made 
explicit, so that the consumers of modelling results can judge their plausibility.
GP4.3. Inputs should be reviewed to assess whether there are any conflicts between 
different data sources; if conflicts exist, they should be investigated. If conflicting 
sources of evidence are available as model inputs (e.g. different estimates of the 
current TB disease burden), it can be useful to estimate results separately under 
both sets of assumptions. If outcomes of interest (typically, the incremental effects 
of policies, or planning or intervention scenarios relative to each other) are sensitive 
to the choice of inputs, this uncertainty should be highlighted in the results.
GP4.4. Modelling commonly makes use of routinely collected data (e.g. monitoring 
indicators and routine surveillance) for parameterization and calibration. In many 
settings these data can be incomplete, be affected by various biases or measure 
outcomes that differ from those being estimated by the model. When using such 
data, it is important to carefully examine how the data were generated to make 
sure they are used appropriately.
GP4.5. Expert opinion commonly plays a role in applied modelling exercises. 
Where expert opinion is used, efforts should be made to corroborate the model-
ling decisions informed by expert opinion; for example, through comparisons with 
data-derived values from different settings. For influential parameters it may be 
prudent to seek data from multiple experts using formal elicitation techniques, and 
account for the variance in opinion. 
GP4.6. Even with an exhaustive review of available evidence, there is likely to be 
substantial uncertainty around multiple model parameters. This uncertainty should 
be investigated to understand the implications for model results. Two common 
approaches for doing so are:
 deterministic sensitivity analyses for individual parameters or groups of 
parameters, which can reveal how the model reacts to different assumptions 
about specific inputs; and 
 probabilistic sensitivity analysis (PSA, or second-order Monte Carlo simulation), 
whereby uncertainty in all input parameters is propagated through the model 
to provide information on the possible distribution of model results. 
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These approaches provide different information and are not mutually exclusive. 
Deterministic sensitivity analysis can help stakeholders develop intuition about 
how the model works, and identify parameter combinations that would lead one 
policy to be preferred over another. PSA can provide information on the aggregate 
uncertainty in model results, and thus allow decision-makers to make an informed 
judgment about the risks associated with using uncertain predictions to inform 
programme planning. PSA results must be interpreted carefully, because the many 
simplifying assump tions involved in an analysis can artificially restrict the range of 
uncertainty, and the actual uncertainty around model predictions may be greater 
than that estimated by PSA.
GP4.7. Model calibration can be accomplished by several methods. Manual 
calibration can yield reasonable results when there is a single parameter or a small 
number of parameters to be fitted. However, this approach can be challenging 
when the number of parameters is larger, in which case, automated methods may 
be preferred. Where calibration is undertaken, results should be accompanied 
by a report of the fit of the model to the calibration data and a description of the 
methods used to achieve calibration. 
3.5 Principle 5 – Validation 
Where possible, model results should be compared with evidence not used 
for model parameterization or calibration, to understand the con sistency 
of modelling results with other evidence. Given the complexity and number 
of assumptions involved in mathematical models, it is difficult to confirm that the 
model will produce valid results by scrutinizing model inputs and structure. Further 
confirmation that a model is operating correctly can be gained by comparing 
model results to other evidence; examples include the results of empirical studies 
or similar modelling efforts, or the experience of experts familiar with the subject 
matter. None of these comparisons can fully guarantee that the results of a 
particular analysis are valid; instead, they either provide confirmation that some 
aspects of model predictions are consistent with external data, or reveal conflicts 
for further investigation. 
3.5.1 Good practices (Principle 5 – Validation)
GP5.1. Although validation is important in mathematical modelling, it is unusual 
to have an opportunity to validate the outcomes of interest, such as total budget 
impact, DALYs averted or incremental cost–effectiveness ratios for competing 
policies or for planning or intervention scenarios. Moreover, model validation 
undertaken in one setting and to answer one particular question does not 
necessarily imply that the results will be valid for other settings and questions. 
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Therefore, modelling should avoid general claims of validity, and should actively 
seek to test model performance in each new application.
GP5.2. Where possible, model results should be checked to ensure that they 
reproduce known features of local disease burden and health service characteristics 
(e.g. TB case notifications, results from TB prevalence surveys, treatment outcome 
data and TB programme budgets), as well as general features of TB epidemiology 
(e.g. the probability and timing of active disease for individuals with latent TB 
infection [LTBI]).
GP5.3. Sensitivity of results to major assumptions should be identified, discussed 
with mod elling stakeholders and reported with the results. As far as possible, this 
process should consider structural as well as parametric assumptions.
GP5.4. Where possible, results should be compared to other modelling results 
or to empirical assessments that have examined the same question or questions. 
These comparisons are unlikely to be exact, and comparisons between the results 
of different models will be less informative if the models themselves are similar. 
However, even if such comparisons are imperfect, they can help to corroborate 
findings in situations where rigorous validation is difficult to achieve. Results may 
also be validated through consultation with local subject-matter experts.
GP5.5. When modelling examines scenarios that are radically more aggressive 
than current approaches to TB prevention and care, this can challenge the 
appropriateness of modelling assumptions, even though the assumptions might 
be reasonable for evaluating less aggressive scenarios. In this context, it is useful 
to check the rates of decline in TB burden (i.e. LTBI prevalence, TB incidence and TB 
mortality) suggested by the model with historical evidence about the maximum 
plausible rates of decline. For example, the fastest national decline in TB incidence 
achieved in the past has not exceeded about 10% per year. 
3.6 Principle 6 – Informativeness 
Modelled analyses should report a rich set of results describing policy 
consequences for a range of outputs and outcomes, to provide a deeper 
understanding of the scenarios being modelled and model functioning. TB 
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In practice: Validation (Principle 5)
In another recent modelling application, multiple models were available 
to be used. By fitting several models to the same epidemiological setting 
and comparing results, modellers were able to identify inconsistencies for 
greater scrutiny. In turn, this led to refinements in the modelling approach and 
interpretation of input data.
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policy or planning options are likely to have implications for a range of different 
outcomes of interest to decision-makers. For example, an intervention that 
improves the quality of TB care in marginalized communities will most immediately 
reduce morbidity and mortality for individuals with active TB disease, but could also 
have implications for Mycobacterium tuberculosis transmission and TB incidence, 
trends in TB drug resistance and the socioeconomic distribution of TB burden. 
In a conventional economic evaluation, these various outcomes are combined 
in a single measure of health benefit (e.g. DALYs averted or deaths averted) to 
summarize the overall health implications of each of the alternative options 
being considered. Calculating a single summary metric facilitates the process of 
identifying the optimal choices (e.g. policies that maximize health benefits for a 
given budget envelope).
Nonetheless, these summary measures may not capture all health outcomes of 
interest to decision-makers. For example, aggregate measures such as DALYs do not 
describe the distribution of health benefits across the population, yet distributional 
information will be relevant if reducing inequality is a policy goal. Similarly, changes 
in trends in TB drug resistance may have little impact on health outcomes over the 
time frame of the analysis, but will affect the long-term viability of TB treatment 
options, a key concern for TB programmes.
Reporting results for multiple outputs and outcomes (in addition to summary 
health measures) can provide a more complete description of the consequences of 
the different options being considered. Moreover, providing a rich set of results to 
decision-makers can help them to develop a deeper understanding of how policies 
or interventions work, how different outcomes relate to each other, and the timing 
of effects.
Similar considerations apply to resource needs estimates generated by models. 
Although an aggregate estimate of resource implications is often required, it is also 
useful to provide cost estimates disaggregated according to when resources will 
In practice: Informativeness (Principle 6)
During a multicountry modelling exercise to examine the impact of radically 
expanded TB programmes, it became clear that epidemiological outcomes 
alone were not sufficient to judge the plausibility of modelled strategies To allow 
county programme experts to judge the feasibility of a strategy, models were 
used to predict additional outcomes describing the changes in programme 
performance required to achieve greater impact; examples of such changes are 
numbers needing to be screened and improvements in cure rates. In some cases 
this led to the original strategy descriptions being judged implausible; in such 
cases, strategies were revised to be more realistic.
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be needed, what budget they will be funded from, and how they compare with 
existing health system budgets and expenditures.
Finally, reporting a more informative set of results – for example, describing the 
intermediate outcomes between inputs and health impact – can provide additional 
reality checks, allowing modelling participants to confirm that anticipated 
programme changes are plausible.
3.6.1 Good practices (Principle 6 – Informativeness)
GP6.1. Modelled analyses should report the effects of policies or planning or 
intervention scenarios on a summary measure of health benefit – such as DALYs 
averted or quality-adjusted life years (QALYs) saved – that aggregate consequences 
for both survival and quality of life. These synthetic measures should be calculated 
using conventional methods, and should describe key analytic decisions such as 
disability weights and life tables used. Life years saved may be used to compare 
policies primarily aimed at averting mortality, but inclusion of changes in quality of 
life can allow broader comparisons.
GP6.2. In addition to summary measures of health benefit, modelled analyses 
should report a rich set of results describing a range of outputs and outcomes that 
might be relevant to decision-makers.
GP6.3. Resource needs estimates generated by modelling should disaggregate es-
timates of total cost or resource needs into categories that are relevant for budg-
eting (e.g. by payer, cost category and year), to provide a granular description of 
where and when resources will be needed.
GP6.4. Modelled analyses should report the relative timing of health benefits and 
costs produced by the model. TB interventions typically yield health benefits that 
are substantially lagged relative to their costs; hence, the choice of time horizon 
can be important. When a short time horizon is adopted, analysts should consider 
whether substantial consequences (in terms of both costs and benefits) have been 
omitted from the analysis, potentially through sensitivity analysis.
3.7 Principle 7 – Transparency 
Modelling results should be accompanied by a clear description of the 
evidence that supports the main findings, the limitations of the modelling 
approach, uncertainty in modelled estimates and the sensitivity of results 
to different assumptions. Conflicts of interest should be avoided if possible, 
but where they are unavoidable they should be described explicitly. 
Models typically reach a level of complexity that makes their mechanisms 
difficult to understand for anyone lacking the time to read and review extensive 
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documentation, particularly stakeholders who are less familiar with modelling 
methods. During the course of model development, it is common to have to make 
assumptions that have only weak empirical support. However, because of the sheer 
number of assumptions being made it is difficult for a consumer of modelling 
results to know which assumptions are important and which have only minor 
influence on the outcomes of primary interest. Despite this situation, it is critical 
that consumers of modelling results have the information available to understand 
the strengths and limitations of modelling results, any threats to validity, and which 
factors relevant to decision-making are considered in the model and which are not 
(and therefore may need to be considered separately). 
The fact that modelled analyses are complicated and subject to many analytic 
decisions means that conflicts of interest can be particularly problematic. Conflicts 
may arise where a particular decision involves significant commercial, professional 
or other interests. If analytic approaches are chosen in order to favour a preferred 
outcome, this may not be apparent to a non-expert audience, or even to an 
expert audience aware of the range of possible modelling approaches. Therefore, 
important conflicts of interest among the participants in a modelling process 
should be identified and avoided where possible. It may not always be possible to 
avoid conflicts, in which case an explicit statement describing the conflicts should 
be presented with the results, such that the results can be evaluated in the context 
of this information.
3.7.1 Good practices (Principle 7 – Transparency)
GP7.1. Full details about the structure and implementation of the model should 
be made available through detailed technical documentation, including the 
parameter values used and their ranges, with a justification of values chosen. 
Although it is unlikely that a model would be replicated to validate the analytic 
results, the documentation should be detailed enough to make this possible. Clear 
information should also be available on any adaptations made to the model for 
a particular application. Ideally, computer programming code should be made 
In practice: Transparency (Principle 7)
During the preparation of modelling results for use in a country application to the 
Global Fund, the structure of the model, and its strengths and limitations, were 
discussed at length with in-country stakeholders. In addition, a smaller in-country 
modelling team tested the key assumptions and model functionality. Opening 
up the “black box” led to critical questions being raised, which helped to improve 
model structure and documentation, and also the calibration of the model to 
country data.
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available, and the modelling team should be available to answer questions about 
the model. 
GP7.2. A detailed description of the alternative scenarios assessed in a particular 
application, and how these were developed, should be produced. Many 
applications include a comparison with a “business-as-usual” base case, and this 
should also be clearly described.
GP7.3. Results reported by the modelled analysis should be accompanied by a 
non-technical description of uncertainties and limitations, the evidence sources 
supporting major assumptions, and the extent to which the model has been 
validated for the research question at hand. Discussion of uncertainty should 
ideally consider how this might affect decision-making (e.g. should major policy 
decisions be delayed until further studies have been conducted and more evidence 
is available?).
GP7.4. In situations where modelling results might be contentious, additional 
efforts should be made to engage all important stakeholders early in the modelling 
process, and seek broad review, input and agreement on draft versions of policy 
scenarios and results. Information should also be reported on the approach that 
was used to identify participants in the modelling. 
GP7.5. At the planning stage of a modelling exercise, any major conflicts of interest 
for parties involved in the modelling should be identified, and a plan developed for 
managing them. 
GP7.6. It can be useful to seek external expert review of the modelling approach 
and results. External review – either at a point when analyses can be revised, or 
after modelling has been completed – can help donors or local decision-makers 
judge the strengths and limitations of the analysis, and better understand the 
implications of results for decision-making.
3.8 Principle 8 – Timeliness
Modelling activities should be organized to provide results at the time they 
are required for decision-making. Ideally, this principle would not conflict with 
the other principles. However, in practice, the need to produce results quickly can 
reduce the opportunities to test all aspects of a model; it can also reduce the time 
and opportunities for stakeholders to review results, raise questions and refine 
scenarios. 
3.8.1 Good practices (Principle 8 – Timeliness)
GP8.1. At the start of a modelling project, identify when modelling evidence 
is needed to support decision-making, and develop a time frame to meet that 
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target, including sufficient time for review and revision of scenarios and modelling 
assumptions.
GP8.2. It may be necessary to cut corners if modelling results are required 
urgently to meet a particular decision-making deadline (e.g. sensitivity analyses or 
stakeholder engagement may be more limited). In these situations, the drawbacks 
of such an abbreviated process should be explicitly described. 
3.9 Principle 9 – Country ownership
Modelling should be conducted with the full participation of local 
stakeholders at each stage of the process. Modelling is more likely to be useful 
and the results used when it is conducted with the full participation of relevant 
stakeholders. Their involvement means that modelling assumptions and modelled 
scenarios are more likely to be appropriate, and that results are more likely to 
be fully understood and considered by policy-makers when making decisions. 
Country ownership is not guaranteed in situations where modelling is conducted 
by external technical experts, and where the need for modelling and the format 
of the planning exercise are dictated by external funding agencies. In such 
situations, greater efforts may be needed to gain full engagement of all important 
stakeholders. In any country there will be existing initiatives for the collection and 
use of data to inform programme planning. Coordination with these efforts will 
In practice: Timeliness (Principle 8)
A country application was timed to evaluate the impact of reforming a national 
TB programme. The model team captured the current TB epidemic and response, 
as well as alternative response scenarios, using findings from a pilot project on 
patient-centred care, which had recently become available. Results outlining an 
optimized TB response strategy were reviewed and released in time to inform a 
dialogue around national TB care. During this dialogue agreement was reached 
on key components of reform to the NTP.
In practice: Country ownership (Principle 9)
In a recent country modelling application undertaken in the context of a Global 
Fund grant, there was a strong emphasis on country leadership and engagement 
from the outset. A country modelling team was created, with representation from 
all major organizations working on TB in the country, including the NTP, the WHO 
country office and the principle recipient of the Global Fund. Following training 
in the use of the modelling tools, the country modelling team led the planning, 
execution and communication of the modelling work, for both domestic and 
international stakeholders.
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improve the quality of data available for modelling, and reduce the chance that 
decision-makers receive conflicting policy advice.
3.9.1 Good practices (Principle 9 – Country ownership)
GP9.1. An initial task of a modelling project is to identify and engage relevant 
country stakeholders. Typically, the NTP will be involved in any modelling exercise 
concerned with the TB response; however, it may also be helpful to include 
representatives of other organizations. These could include nongovernmental 
organizations (NGOs) engaged in providing care, patient advocacy organizations, 
local subject-matter experts, and local representatives of international funders and 
technical partners. 
GP9.2. To aid model choice, the desire for in-country capacity-building should be 
assessed and addressed early on in the project. This could involve anything from 
enabling key partners in the NTP to critically examine model assumptions and 
results, to building the capacity needed to operate the model without external 
technical assistance. 
GP9.3. Country input should be enabled at each stage of the modelling process. 
This includes parameterization and calibration (i.e. determining whether key 
epidemiological and cost targets are reflected satisfactorily), decisions on inter-
vention scenarios and review of modelling results before dissemination to a wider 
audience. 
GP9.4 Any new modelling application should be planned in the light of existing 
efforts in research, evaluation, surveillance and technical assistance designed to 
inform policy and planning.
GP9.5. If modelling is to be undertaken by an external technical assistance provider, 
the choice of provider should depend on their ability to meet the country decision-
makers’ needs. These considerations can include familiarity with the setting and 
questions of interest, whether the proposed approach (format for the modelling 
project) will produce results within the required time frame, and whether it will 
provide sufficient opportunities for input and critical review of modelling results. 
The linked catalogue1 provides detailed information on organizations currently 
engaged in providing country technical assistance for TB modelling (although this 
is not exhaustive).
1 See https://docs.google.com/spreadsheets/d/1vEDYkXJbMhftWDojnWOuVDbH6h9__Jezg0xsqH5MfJo/
edit#gid=287565855
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3.10 Principle 10 – Iteration
Modelling should involve an iterative process of engagement, and should 
be reconsidered in light of new evidence. Given the complexity of modelling 
and decision-making, an iterative process is likely to be needed for identifying 
candidate policies or interventions, and the evidence to describe them. Hence, the 
modelling approach needs to allow for iteration between adaptation of the model 
and evaluation of results. Once a modelling exercise is complete, the results should 
remain open to criticism and revision in light of new evidence, and a clear way 
forward to improving the process should be identified.
3.10.1 Good practices (Principle 10 – Iteration)
GP10.1. In a given modelling application there should be multiple opportunities for 
review of model scenarios and results by key stakeholders. Explanations should be 
sufficient for stakeholders to understand major analytic decisions and assumptions, 
and allowance should be made for analyses to be revised in light of feedback. 
GP10.2. Modelling results should be accompanied by an explanation of the 
sensitivity of results to new evidence, research that would be useful to validate the 
modelled results, and findings that should trigger revision of the analysis.
GP10.3. As new policies are introduced, early programmatic data can be used to 
check assumptions made during modelling. If modelling assumptions are incorrect, 
the validity of longer term projections should be reconsidered. If necessary, model 
projections may be updated based on actual implementation data.
In practice: Iteration (Principle 10)
Estimates of disease burden (e.g. those from WHO’s Global TB report) are released 
annually as new surveillance and survey data become available. Modelling groups 
have evaluated past modelling projections and results in the light of new burden 
estimates or data, such as prevalence surveys or inventory studies. As part of 
preparations for a Global Fund application, one modelling group returned to 
previous projections and reviewed these in the context of new prevalence survey 
data.
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CHAPTER 4
The modelling process
Fig. 4.1 links the principles and good practices to the actions undertaken in a 
typical modelling application. The flowchart describes the sequence of actions and 
linked principles that are relevant for each particular action, and the stakeholder or 
stakeholders that would typically take the lead for each principle.
The first stage of the modelling process is to define the decision or problem. This 
includes the various aspects described under Principle 1 (Section 3.1), including 
identifying the decision-maker, and defining the policies to be compared and 
the outcomes of interest. An important question at this early stage is whether 
mathematical modelling is the right approach to answer the policy question, given 
the other approaches that could be used. Where modelling is decided to be the 
right approach, the next step is to identify important stakeholders and relevant 
experts, and form the project team that will collaborate on the modelling exercise. 
Once these have been determined, the next step is to define the time frame in which 
the work will be done, and how this fits into the policy and planning cycle. This 
leads to the choice of model used – in particular, the identification of any existing 
models that meet the required need. For any available models, the suitability of the 
model to the question, particularly with regard to model structure (e.g. whether 
it includes relevant risk groups, stratifications, interventions or epidemiological 
characteristics), should be examined. In addition, suitability of a model structure 
will depend on the time and labour requirements to undertake the analysis, and 
the ability to provide training and capacity development, if requested. In some 
situations, there will only be one model available for a particular application, but 
this does not remove the need to critically evaluate its suitability for the country 
context and policy questions being asked. 
Once a model has been chosen, the next step is to identify the required data 
(e.g. burden estimates and impact and cost estimates of likely interventions), and 
determine how and where these data will be obtained, and what steps will be taken 
to address any data gaps (e.g. additional data collection, or assumptions based 
on expert opinion). Each of the actions described above feeds back into previous 
actions; hence, it is important to iteratively adapt each of the actions within this first 
stage. 
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Once the first stage has been firmly established, the next step is to identify the 
required resources for the work, including, for example:
 the required expertise in terms of in-country decision-makers, epidemiologists 
and costing experts, as well as technical assistance; 
 the availability of sufficient funding for the work, whether from in-country or an 
external donor; and
 a plan for development of institutional or in-country capacity, to ensure that the 
work can be continued in the future. 
This is the point at which to formally form the modelling team, typically with an 
external modelling group. Once the team has been formed, the model can begin 
to be used to generate results, which should then be examined and interpreted by 
the relevant experts.
The subsequent stage, reporting of the model results, highlights the need to 
describe key assumptions made in the modelling, to include the sources of various 
data used, describe the model results and identify limitations to the modelling 
approach. More detail relevant to this section can be found under Principle 7 
(transparency).
Finally, follow-up is needed after the reporting of model results. This includes 
follow-up related to the translation of results into action, helping to ensure the 
sustainability of the process, and testing of the model as new data become 
available.
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FIG. 4.1  Flowchart of steps involved in a typical modelling project1
1 Also displayed are the suggested lead actors for each step in the modelling process; that is, the individual 
or group primarily responsible for implementing principles from a given practice. Actors include 
 G in-country decision-makers, ( in-country experts
 ® modellers and U international funders. 
 Other actors may also have a role in contributing towards activities, or in creating the demand for them. 
Although all relevant principles are listed here, in reality, not all good practices for each principle or 
indeed all lead actors for each good practice will be relevant to a given step in the process. The leads 
listed here for each activity therefore do not match exactly with all of the leads for a given practice listed 
in Table 3.1.
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